Myopia: Improving lifestyles

A total of 144 children around the world have taken part in CooperVision’s MiSight 1 day clinical trial since it launched in 2012. The study, which was initially a three-year study in Canada, Portugal, Singapore and the UK, is now in its final year and has achieved US Food and Drug Administration approval for MiSight 1 day.

The first phase of the study tested the efficacy of its soft contact lens in slowing the progression of myopia against an equivalent single vision one day lens. Its effectiveness in slowing change in spherical equivalent refraction and axial length was demonstrated in a report after the first three years. Five-year data presented in 2019 found that treatment efficacy does not depend on previous treatments and revealed that children can wear the contact lenses with minimal impact on ocular physiology. The final year of the trial has assessed participants one year after cessation of MiSight lens wear to investigate rebound effects in adolescents.